Published in Transplantation on August 27, 1996
Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes. Kidney Int (2013) 1.48
Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int (2003) 1.19
Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosuppressive regimens. J Osteoporos (2011) 0.83
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science (1992) 5.36
Liver transplantation in children from living related donors. Surgical techniques and results. Ann Surg (1991) 3.32
Transplantation of liver grafts from living donors into adults--too much, too soon. N Engl J Med (2001) 2.61
Ethics of liver transplantation with living donors. N Engl J Med (1989) 2.47
Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg (1990) 2.37
Attitudes of minority patients with end-stage renal disease regarding ABO-incompatible list-paired exchanges. Am J Transplant (2006) 2.33
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Myocardial ischemia during cocaine withdrawal. Ann Intern Med (1989) 2.21
Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol (1984) 2.12
Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant (2013) 1.99
Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease. Hepatology (1989) 1.84
Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation (1995) 1.82
Equal Opportunity Supplemented by Fair Innings: equity and efficiency in allocating deceased donor kidneys. Am J Transplant (2012) 1.73
Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg (2000) 1.73
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
The ethical assessment of innovative therapies: liver transplantation using living donors. Theor Med (1990) 1.67
Ethics of a paired-kidney-exchange program. N Engl J Med (1997) 1.66
Liver transplantation with reduced-size donor organs. Transplantation (1988) 1.66
A mouse model for polyomavirus-associated nephropathy of kidney transplants. Am J Transplant (2006) 1.65
Transplantation of two patients with one liver. Analysis of a preliminary experience with 'split-liver' grafting. Ann Surg (1990) 1.64
Increased utilization of organ donors: transplantation of two recipients from single donor livers. Transplant Proc (1990) 1.61
Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant (2011) 1.59
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol (1997) 1.55
Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant (2011) 1.54
Liver transplantation in children. Ann Surg (1991) 1.51
Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg (1990) 1.45
Liver transplantation, including the concept of reduced-size liver transplants in children. Ann Surg (1988) 1.44
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation (1999) 1.43
The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am J Clin Nutr (2001) 1.42
Susceptibility of prosthetic biomaterials to infection. Surg Endosc (2005) 1.41
Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant (2006) 1.38
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 1.36
Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis (1998) 1.35
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant (2010) 1.31
Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. Lancet (1993) 1.28
Portal vein thrombosis and stenosis in pediatric liver transplantation. Transplantation (1996) 1.27
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry (2012) 1.27
Immunosuppression and Merkel cell cancer. Transplant Proc (2002) 1.25
Biliary strictures complicating liver transplantation. Incidence, pathogenesis, management, and outcome. Ann Surg (1992) 1.23
The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation (1990) 1.21
Biliary complications in pediatric liver transplantation. A comparison of reduced-size and whole grafts. Transplantation (1992) 1.20
Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation (1984) 1.20
Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol (1999) 1.20
Surgical management of benign tumors of the liver. Int J Gastrointest Cancer (2001) 1.19
Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant (2011) 1.18
Miles to go…. Am J Transplant (2011) 1.17
Reliability and validity of the appraisal of diabetes scale. J Behav Med (1991) 1.17
Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc (2005) 1.17
Liver transplantation for primary or metastatic sarcoma to the liver. Am J Transplant (2006) 1.16
A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation (1994) 1.16
Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation (1998) 1.15
Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol (1987) 1.14
Effect of class II antigen matching on renal allograft survival in miniature swine. J Exp Med (1984) 1.14
Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation (1996) 1.14
Choledochal cyst followed by carcinoma of the hepatic duct. South Med J (1967) 1.13
Portal vein stenosis in children with segmental liver transplants: treatment with percutaneous transhepatic venoplasty. AJR Am J Roentgenol (1995) 1.13
The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol (2001) 1.13
Effect of a prior portasystemic shunt on subsequent liver transplantation. Ann Surg (1989) 1.12
One thousand liver transplants. The lessons learned. Ann Surg (1994) 1.12
Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant (2009) 1.11
Is any method of vascular control superior in hepatic resection of metastatic cancers? Longmire clamping, pringle maneuver, and total vascular isolation. Arch Surg (2001) 1.11
Allograft rejection in pediatric recipients of living related liver transplants. Hepatology (1996) 1.10
Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med (1995) 1.09
The assessment of anxiety and fear in persons with chronic pain: a comparison of instruments. Behav Res Ther (1997) 1.09
Complications in 100 living-liver donors. Ann Surg (1998) 1.07
Choledochocholedochostomy without a T tube or internal stent in transplantation of the liver. Surg Gynecol Obstet (1990) 1.06
When the living and the deceased cannot agree on organ donation: a survey of US organ procurement organizations (OPOs). Am J Transplant (2014) 1.05
Hepatic artery reconstruction during liver transplantation. Transplantation (1989) 1.05
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res (1982) 1.03
Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation (1999) 1.02
Donor lymphoid organs are a major site of alloreactive T-cell priming following intestinal transplantation. Am J Transplant (2006) 1.01
Hepatic resection: effective treatment for primary and secondary tumors. Surgery (2000) 1.01
Primary living-donor liver transplantation at the University of Chicago: technical aspects of the first 104 recipients. Ann Surg (2000) 1.01
Successful hepatic transplantation in congenital absence of recipient portal vein. Surgery (1990) 1.00
Bacterial infection as a complication of liver transplantation: epidemiology and risk factors. Rev Infect Dis (1991) 0.99
Jejunal diverticulosis with perforation as a complication of Fabry's disease. Gastroenterology (1984) 0.98
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol (1992) 0.98
Granulomatous tubulointerstitial nephritis in the renal allograft. Am J Kidney Dis (2000) 0.97
Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol (2000) 0.97
General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc (1993) 0.97